评价益生菌和蜂胶提取物对幽门螺杆菌感染Wistar大鼠胃组织生长和组织病理学变化的抑制作用。

IF 1.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Iranian Journal of Pharmaceutical Research Pub Date : 2024-12-25 eCollection Date: 2024-01-01 DOI:10.5812/ijpr-148158
Roghayeh Kiani, Naheed Mojgani, Farzad Kobarfard, Parvaneh Saffarian, Seyed Abdulmajid Ayatollahi, Mona Khoramjouy
{"title":"评价益生菌和蜂胶提取物对幽门螺杆菌感染Wistar大鼠胃组织生长和组织病理学变化的抑制作用。","authors":"Roghayeh Kiani, Naheed Mojgani, Farzad Kobarfard, Parvaneh Saffarian, Seyed Abdulmajid Ayatollahi, Mona Khoramjouy","doi":"10.5812/ijpr-148158","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> is a significant contributor to a range of gastrointestinal conditions, with conventional treatment methods primarily relying on antibiotics. However, the rise of antibiotic-resistant strains has necessitated the exploration of alternative therapeutic approaches.</p><p><strong>Objectives: </strong>To determine the <i>in vitro</i> antibacterial potential of probiotic bacteria (<i>Lacticaseibacillus rhamnosus</i> BLRH 260 and <i>Limosilactobacillus reuteri</i>) and four propolis extracts against <i>H. pylori</i> and to analyze their impacts on body weight index and histopathological changes in <i>H. pylori</i>-challenged Wistar rats.</p><p><strong>Methods: </strong>The inhibitory effects of probiotic bacteria (<i>L. rhamnosus</i> BLRH 260 and <i>L. reuteri</i>) and propolis extracts on the growth of <i>H. pylori</i> were evaluated using an agar well diffusion assay. In vivo analysis involved fifty-four male Wistar rats (200 - 250 g) infected with an <i>H. pylori</i> suspension (10<sup>8</sup> CFU/mL) and orally administered propolis or probiotics (10<sup>8</sup> CFU/mL) via gavage for 21 days. The effects of different treatments on body weight and histopathological changes in gastric tissue samples were assessed, and the results were statistically analyzed.</p><p><strong>Results: </strong>The tested propolis extracts and the supernatant fluids from the mentioned probiotic strains showed significant antibacterial activity against <i>H. pylori</i> in the agar well diffusion assay, with notable variations. In vivo, the findings demonstrated that oral administrations of propolis and probiotics, either separately or in combination, led to significant increases in body weight and amelioration of histopathological changes in gastric tissue samples, particularly in terms of erosion depth, hemorrhagic inflammation, and apoptosis in the infected animals. Histopathological differences between antibiotic-treated animals and those receiving other treatments were observed, with significant differences.</p><p><strong>Conclusions: </strong>The results of this study underscore the potential therapeutic benefits of propolis and probiotics in addressing <i>H. pylori</i>-induced gastropathy. Additional research is necessary to clarify the mechanisms involved and to refine dosage and treatment protocols for optimal effectiveness.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"23 1","pages":"e148158"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892748/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating the Inhibitory Effects of Probiotic Bacteria and Propolis Extracts on the Growth and Histopathological Changes in Gastric Tissues of <i>Helicobacter pylori</i> Challenged Wistar Rats.\",\"authors\":\"Roghayeh Kiani, Naheed Mojgani, Farzad Kobarfard, Parvaneh Saffarian, Seyed Abdulmajid Ayatollahi, Mona Khoramjouy\",\"doi\":\"10.5812/ijpr-148158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong><i>Helicobacter pylori</i> is a significant contributor to a range of gastrointestinal conditions, with conventional treatment methods primarily relying on antibiotics. However, the rise of antibiotic-resistant strains has necessitated the exploration of alternative therapeutic approaches.</p><p><strong>Objectives: </strong>To determine the <i>in vitro</i> antibacterial potential of probiotic bacteria (<i>Lacticaseibacillus rhamnosus</i> BLRH 260 and <i>Limosilactobacillus reuteri</i>) and four propolis extracts against <i>H. pylori</i> and to analyze their impacts on body weight index and histopathological changes in <i>H. pylori</i>-challenged Wistar rats.</p><p><strong>Methods: </strong>The inhibitory effects of probiotic bacteria (<i>L. rhamnosus</i> BLRH 260 and <i>L. reuteri</i>) and propolis extracts on the growth of <i>H. pylori</i> were evaluated using an agar well diffusion assay. In vivo analysis involved fifty-four male Wistar rats (200 - 250 g) infected with an <i>H. pylori</i> suspension (10<sup>8</sup> CFU/mL) and orally administered propolis or probiotics (10<sup>8</sup> CFU/mL) via gavage for 21 days. The effects of different treatments on body weight and histopathological changes in gastric tissue samples were assessed, and the results were statistically analyzed.</p><p><strong>Results: </strong>The tested propolis extracts and the supernatant fluids from the mentioned probiotic strains showed significant antibacterial activity against <i>H. pylori</i> in the agar well diffusion assay, with notable variations. In vivo, the findings demonstrated that oral administrations of propolis and probiotics, either separately or in combination, led to significant increases in body weight and amelioration of histopathological changes in gastric tissue samples, particularly in terms of erosion depth, hemorrhagic inflammation, and apoptosis in the infected animals. Histopathological differences between antibiotic-treated animals and those receiving other treatments were observed, with significant differences.</p><p><strong>Conclusions: </strong>The results of this study underscore the potential therapeutic benefits of propolis and probiotics in addressing <i>H. pylori</i>-induced gastropathy. Additional research is necessary to clarify the mechanisms involved and to refine dosage and treatment protocols for optimal effectiveness.</p>\",\"PeriodicalId\":14595,\"journal\":{\"name\":\"Iranian Journal of Pharmaceutical Research\",\"volume\":\"23 1\",\"pages\":\"e148158\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892748/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5812/ijpr-148158\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr-148158","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:幽门螺杆菌是一系列胃肠道疾病的重要贡献者,传统的治疗方法主要依赖于抗生素。然而,抗生素耐药菌株的增加已经有必要探索替代治疗方法。目的:测定鼠李糖乳杆菌BLRH 260和罗伊氏乳酸杆菌等益生菌及4种蜂胶提取物对幽门螺杆菌的体外抑菌潜力,并分析其对幽门螺杆菌感染Wistar大鼠体重指数和组织病理学变化的影响。方法:采用琼脂孔扩散法测定益生菌(鼠李糖乳杆菌BLRH 260和罗伊氏乳杆菌)和蜂胶提取物对幽门螺杆菌生长的抑制作用。体内实验采用54只雄性Wistar大鼠(200 - 250 g)感染幽门螺杆菌混悬液(108 CFU/mL)和口服蜂胶或益生菌(108 CFU/mL)灌胃21天。评估不同治疗方法对大鼠体重及胃组织标本组织病理学变化的影响,并对结果进行统计学分析。结果:各菌株蜂胶提取物和上清液在琼脂孔扩散实验中对幽门螺杆菌具有显著的抑菌活性,且差异显著。在体内,研究结果表明,口服蜂胶和益生菌,无论是单独还是联合,都能显著增加体重,改善胃组织样本的组织病理学变化,特别是在感染动物的侵蚀深度、出血性炎症和细胞凋亡方面。观察了抗生素治疗动物和其他治疗动物之间的组织病理学差异,差异显著。结论:本研究结果强调蜂胶和益生菌在治疗幽门螺杆菌性胃病方面的潜在治疗益处。需要进一步的研究来阐明所涉及的机制,并改进剂量和治疗方案以获得最佳效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating the Inhibitory Effects of Probiotic Bacteria and Propolis Extracts on the Growth and Histopathological Changes in Gastric Tissues of Helicobacter pylori Challenged Wistar Rats.

Background: Helicobacter pylori is a significant contributor to a range of gastrointestinal conditions, with conventional treatment methods primarily relying on antibiotics. However, the rise of antibiotic-resistant strains has necessitated the exploration of alternative therapeutic approaches.

Objectives: To determine the in vitro antibacterial potential of probiotic bacteria (Lacticaseibacillus rhamnosus BLRH 260 and Limosilactobacillus reuteri) and four propolis extracts against H. pylori and to analyze their impacts on body weight index and histopathological changes in H. pylori-challenged Wistar rats.

Methods: The inhibitory effects of probiotic bacteria (L. rhamnosus BLRH 260 and L. reuteri) and propolis extracts on the growth of H. pylori were evaluated using an agar well diffusion assay. In vivo analysis involved fifty-four male Wistar rats (200 - 250 g) infected with an H. pylori suspension (108 CFU/mL) and orally administered propolis or probiotics (108 CFU/mL) via gavage for 21 days. The effects of different treatments on body weight and histopathological changes in gastric tissue samples were assessed, and the results were statistically analyzed.

Results: The tested propolis extracts and the supernatant fluids from the mentioned probiotic strains showed significant antibacterial activity against H. pylori in the agar well diffusion assay, with notable variations. In vivo, the findings demonstrated that oral administrations of propolis and probiotics, either separately or in combination, led to significant increases in body weight and amelioration of histopathological changes in gastric tissue samples, particularly in terms of erosion depth, hemorrhagic inflammation, and apoptosis in the infected animals. Histopathological differences between antibiotic-treated animals and those receiving other treatments were observed, with significant differences.

Conclusions: The results of this study underscore the potential therapeutic benefits of propolis and probiotics in addressing H. pylori-induced gastropathy. Additional research is necessary to clarify the mechanisms involved and to refine dosage and treatment protocols for optimal effectiveness.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
6.20%
发文量
52
审稿时长
2 months
期刊介绍: The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信